Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours

Inclusion Criteria: * Age \>=18 years. * Histological or cytological documentation of non hematologic, malignant solid tumour. * Have failed at least one previous therapeutic regimen. * Measurable disease according to RECIST 1.1. * Life expectancy \>= 12 weeks * ECOG Performance Status of 0 or 1 * Written, signed and dated informed consent * Able and willing to meet all protocol-required treatments, investigations and visits. * Have adequate organ function Exclusion Criteria: * Clinically significant non-malignant disease. * Active CNS metastases. * Subjects with uncontrolled diabetes. * History of clinically significant adverse drug reaction to heparin or other anti-coagulant agents * History of immune-mediated thrombocytopaenia or other platelet abnormalities or other hereditary or acquired coagulopathies. * Concomitant use of aspirin (\> 150 mg/day), NSAIDs (except COX-2 selective inhibitors), vitamin K antagonists (other than low-dose prophylactic use), heparin within two weeks prior to randomisation, or other anti-platelet drugs. * History of severe allergic, anaphylactic or other significant adverse reaction to radiographic contrast media * Known seropositivity to the human immunodeficiency virus (HIV) * Women who are pregnant or breast-feeding. * Women of child-bearing potential and male subjects who are partners of women of childbearing potential who are unable or unwilling to practice a highly effective means of contraception. * Active substance abuse * Subjects who have received an investigational agent within 28 days prior to Cycle 1 Day 1.